Protalix BioTherapeutics

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell PLX and other ETFs, options, and stocks.

About PLX

Protalix Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development, production, and commercialization of recombinant therapeutic proteins based on plant cell based expression system. Its products include Alidornase alfa, PRX-115 and PRX-11.

CEO

Dror Bashan

CEODror Bashan

Employees

206

Employees206

Headquarters

Hackensack, New Jersey

HeadquartersHackensack, New Jersey

Founded

1993

Founded1993

Employees

206

Employees206

PLX Key Statistics

Market cap

57.25M

Market cap57.25M

Price-Earnings ratio

—

Price-Earnings ratio—

Dividend yield

—

Dividend yield—

Average volume

162.95K

Average volume162.95K

High today

$1.13

High today$1.13

Low today

$1.10

Low today$1.10

Open price

$1.10

Open price$1.10

Volume

59.05K

Volume59.05K

52 Week high

$2.00

52 Week high$2.00

52 Week low

$0.70

52 Week low$0.70

PLX News

Yahoo Finance 2h

Protalix Biotherapeutics Hosting Key Opinion Leader Webinar on Fabry Disease and PRX-102 - Yahoo Finance

Webcast to be held on Monday, December 5th at 8:30 a.m. EST CARMIEL, Israel, Dec. 4, 2022 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (T...

Benzinga 5d

Protalix and Chiesi Resubmit FDA Application For Rare Disease Treatment - Avrobio, Freeline - Benzinga

Protalix BioTherapeutics, Inc. PLX, an Israeli biopharmaceutical company, and Chiesi Global Rare Diseases, a business unit of the Chiesi Group, have resubmitted...

PLX Earnings

-$0.25

-$0.17

-$0.08

$0.00

Q1 FY21

Q2 FY21

Q3 FY21

Q4 FY21

Q1 FY22

Q2 FY22

Q3 FY22

Q4 FY22

Estimated

— per share

Estimated— per share

Actual

Expected Mar 30, Pre-Market

ActualExpected Mar 30, Pre-Market